Skip to main content

Vida Ventures, LLC's Form 4 filing

Kyverna Therapeutics, Inc. (KYTX) · filed Feb 14, 2024

Accession no.
0000950170-24-015479
Filed
Feb 14, 2024, 7:04 PM ET
Trade date
Feb 12, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 3 derivative transactions. Open-market purchases total $5.57M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Vida Ventures, LLCCIK 000172448910% Owner
Vida Ventures GP III, L.L.C.CIK 000185550210% Owner
Vida Ventures III-A, L.P.CIK 000185550310% Owner
Vida Ventures III, L.P.CIK 000185550410% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 12, 2024Common StockCConversionAcquired+4,523,924––4,523,924IndirectDuplicate filing
Feb 12, 2024Common StockPPurchaseAcquired+252,553$22.00+$5,556,166252,553Indirect
Feb 12, 2024Common StockPPurchaseAcquired+583$22.00+$12,826583Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 12, 2024Common StockCConversionDisposed−967,188$0.00$00IndirectDuplicate filing
Feb 12, 2024Common StockCConversionDisposed−1,940,388$0.00$00IndirectDuplicate filing
Feb 12, 2024Common StockCConversionDisposed−1,616,348$0.00$00IndirectDuplicate filing

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)